Stats
Actions
Tags
Writes journalist-facing FAQ documents for crisis communications. Anticipates likely questions and provides approved, consistent answers for spokespeople and press officers.
How this skill is triggered — by the user, by Claude, or both
Slash command
/autopunk-media-skills:faq-document-writerThe summary Claude sees in its skill listing — used to decide when to auto-load this skill
Writes a journalist-facing FAQ document for a crisis or complex issue, anticipating the questions journalists are most likely to ask and providing approved, consistent answers that spokespeople and press officers can use verbatim or as a guide.
Writes a journalist-facing FAQ document for a crisis or complex issue, anticipating the questions journalists are most likely to ask and providing approved, consistent answers that spokespeople and press officers can use verbatim or as a guide.
Required: A summary of the incident or issue (what happened, what is confirmed, what is under investigation); the organisation's name and sector; what the most likely journalist questions are, or a brief description of what the media have already asked; what is approved to say and what is not.
Optional: A holding statement or earlier press release for consistency reference; the target channel (internal use only / media-facing / public website); whether unanswerable questions should be flagged rather than answered; a list of specific questions to address; the spokesperson's name and title.
Q&A format with bold questions and plain-text answers. 5–12 Q&A pairs. Each answer 30–80 words. Total document 400–900 words depending on complexity. Optional: thematic section headers if more than six pairs. Tone: calm, authoritative, factual. No bullet points within individual answers unless listing a specific sequence of events. Date and version number at top if requested.
Issue: A pharmaceutical distribution company, Northgate Pharma Distribution, has discovered that a batch of blood pressure medication supplied to 47 pharmacies across the UK contained an incorrect dosage labelling error. The error was identified by an internal quality audit, not a patient complaint. No adverse patient outcomes have been reported. The batch has been recalled. The Medicines and Healthcare products Regulatory Agency (MHRA) has been notified. The cause is under investigation but believed to be a labelling machine fault at the third-party packaging contractor.
Approved to say: The recall is underway, MHRA has been notified, no adverse patient outcomes reported, internal audit identified the error, cause under investigation.
Not approved to say: The contractor's name, any information about litigation or regulatory enforcement action, the total number of units in the batch.
Northgate Pharma Distribution — Media FAQ Issue: Medication Labelling Error and Batch Recall Version 1 — 16 March 2026
Q: What exactly went wrong? A batch of blood pressure medication supplied by Northgate Pharma Distribution was found to contain an incorrect dosage labelling error. The error affects labelling only — the medication itself was correctly manufactured. The batch has been recalled from all 47 pharmacies it was supplied to.
Q: How did you find out about this? The error was identified through our own internal quality audit process. It was not reported by a patient or pharmacist. We are proud that our internal controls detected the issue before any harm occurred.
Q: Has anyone been harmed? We have no reports of any adverse patient outcomes associated with this batch. Patients who received medication from this batch and have concerns are advised to speak to their pharmacist or GP.
Q: Have you notified the regulator? Yes. We notified the Medicines and Healthcare products Regulatory Agency (MHRA) as soon as the error was confirmed. We are cooperating fully with the MHRA and will provide whatever information they require.
Q: What is the cause of the error? The investigation is ongoing. We believe the error relates to a labelling process fault, but we will not confirm the specific cause until the investigation is complete. We expect to have preliminary findings within [X days].
Q: How many packs are affected? Where are they now? We are not disclosing the total volume of the batch at this stage of the investigation. The recall process is underway and all 47 affected pharmacies have been contacted.
Q: Should patients stop taking their medication? No patient should stop taking prescribed medication without speaking to their doctor or pharmacist first. Patients with concerns about this specific batch should contact their dispensing pharmacy, who can advise on next steps.
Q: Will there be regulatory enforcement action? We cannot comment on the possibility of future regulatory action. We are focused on completing the recall, supporting the MHRA's review, and identifying the root cause of the labelling fault.
Internal note: Questions about the packaging contractor's identity and any litigation matters should be referred to the legal team and not addressed by media spokespeople at this time.
npx claudepluginhub ur-grue/autopunk-media-skills --plugin autopunk-media-skillsDrafts crisis holding statements, journalist Q&A posture, and what-not-to-say guidance from confirmed incident facts using proven crisis-comms frameworks.
Drafts crisis communications statements for organisations responding to breaking negative stories, using a three-part structure: Empathy, Action, Information.
Guides writing a PR/FAQ press release and FAQ for product clarity and customer-centric thinking, following Amazon's Working Backwards process.